Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026
The updated clinical data report durable responses and a favorable tolerability profile in heavily pretreated participants with HER2-driven cancers.
The updated clinical data report durable responses and a favorable tolerability profile in heavily pretreated participants with HER2-driven cancers.